 PHILADELPHIA, Aug. 30, 2021 PRNewswire -- Lannett Company, Inc. NYSE: LCI today announced that it has commenced marketing Mycophenolate Mofetil for Oral Suspension USP, 200 mgmL, an internally developed product. Total U.S. sales of Mycophenolate Mofetil for Oral Suspension USP, 200 mgmL, according to IQVIA market, were approximately 68 million for the 12 months ending June 2021, although actual generic market values are expected to be lower. 